Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus
- PMID: 11451689
- PMCID: PMC90646
- DOI: 10.1128/AAC.45.8.2304-2308.2001
Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus
Abstract
The efficacies of orally (p.o.) dosed linezolid and intravenously (i.v.) dosed vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in rabbits with experimental aortic-valve endocarditis were investigated. After endocarditis was established with a recent clinical MRSA isolate, rabbits were dosed for 5 days with linezolid (p.o., three times a day) at either 25, 50, or 75 mg/kg of body weight or vancomycin (i.v., twice a day) at 25 mg/kg. The 25-mg/kg linezolid group had a high mortality rate and bacterial counts in the valve vegetations that were not different from those of the controls. Linezolid dosed p.o. at 50 and 75 mg/kg and i.v. vancomycin produced statistically significant reductions in bacterial counts compared to those of the untreated controls. The reduced bacterial counts and culture-negative valve rates for the animals treated with linezolid at 75 mg/kg were similar to those for the vancomycin-treated animals. Concentrations of linezolid in plasma were determined at several points in the dosing regimen. These results suggest that the efficacy of linezolid in this infection model is related to trough levels in plasma that remain above the MIC for this microorganism. At the ineffective dose of linezolid (25 mg/kg) the concentration at sacrifice was 0.045 times the MIC, whereas the concentrations of linezolid in plasma in the 50- and 75-mg/kg groups were 2 and 5 times the MIC at sacrifice, respectively. The results from this experimental model suggest that the oxazolidinone linezolid may be effective for the treatment of serious staphylococcal infections when resistance to other antimicrobials is present.
Figures

Similar articles
-
Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.J Antimicrob Chemother. 2008 Aug;62(2):381-3. doi: 10.1093/jac/dkn180. Epub 2008 Apr 28. J Antimicrob Chemother. 2008. PMID: 18445576
-
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.Antimicrob Agents Chemother. 2005 Aug;49(8):3163-5. doi: 10.1128/AAC.49.8.3163-3165.2005. Antimicrob Agents Chemother. 2005. PMID: 16048918 Free PMC article.
-
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25. Antimicrob Agents Chemother. 2007. PMID: 17591849 Free PMC article.
-
The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.Curr Med Res Opin. 2010 Mar;26(3):571-88. doi: 10.1185/03007990903512057. Curr Med Res Opin. 2010. PMID: 20055750 Review.
-
[Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].Lijec Vjesn. 2010;132 Suppl 1:11-3. Lijec Vjesn. 2010. PMID: 20715711 Review. Croatian.
Cited by
-
Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study.EBioMedicine. 2021 Mar;65:103281. doi: 10.1016/j.ebiom.2021.103281. Epub 2021 Mar 12. EBioMedicine. 2021. PMID: 33721817 Free PMC article.
-
Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 2003 Aug;47(8):2655-8. doi: 10.1128/AAC.47.8.2655-2658.2003. Antimicrob Agents Chemother. 2003. PMID: 12878535 Free PMC article.
-
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics.Int J Antimicrob Agents. 2014 Mar;43(3):223-30. doi: 10.1016/j.ijantimicag.2013.11.006. Epub 2013 Dec 17. Int J Antimicrob Agents. 2014. PMID: 24389079 Free PMC article. Review.
-
Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2003 Sep;47(9):3002-4. doi: 10.1128/AAC.47.9.3002-3004.2003. Antimicrob Agents Chemother. 2003. PMID: 12937013 Free PMC article.
-
Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23. Antimicrob Agents Chemother. 2015. PMID: 25801564 Free PMC article.
References
-
- Birmingham M C, Craig R R, Hafkin B, Todd W M, Flavin S M, Root J D, Zimmer G S, Batts D H, Schentag J J. Critical care patients with significant, resistant, gram-positive infections enrolled in the linezolid compassionate use protocol. Crit Care Med. 1999;27(12)(Suppl. S):42.
-
- Carbon C. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand J Infect Dis. 1991;74:163–172. - PubMed
-
- Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother. 1999;44:31–36. - PubMed
-
- Chambers H F. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992;30(Suppl. A):117–122. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical